CN114886961A - Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof Download PDFInfo
- Publication number
- CN114886961A CN114886961A CN202210634557.5A CN202210634557A CN114886961A CN 114886961 A CN114886961 A CN 114886961A CN 202210634557 A CN202210634557 A CN 202210634557A CN 114886961 A CN114886961 A CN 114886961A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 119
- 201000005569 Gout Diseases 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 241000271566 Aves Species 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 21
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 16
- 241000132012 Atractylodes Species 0.000 claims abstract description 15
- 241000632227 Antenoron Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims description 72
- 239000007788 liquid Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000001914 filtration Methods 0.000 claims description 26
- 238000002791 soaking Methods 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 238000002137 ultrasound extraction Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 239000003674 animal food additive Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 56
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 26
- 229940116269 uric acid Drugs 0.000 abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 11
- 230000029142 excretion Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 208000003322 Coinfection Diseases 0.000 abstract description 2
- 208000035240 Disease Resistance Diseases 0.000 abstract description 2
- 239000003792 electrolyte Substances 0.000 abstract description 2
- 230000036737 immune function Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 23
- 241000287828 Gallus gallus Species 0.000 description 22
- 235000013330 chicken meat Nutrition 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 17
- 230000008021 deposition Effects 0.000 description 17
- 239000008213 purified water Substances 0.000 description 16
- 244000144977 poultry Species 0.000 description 15
- 235000013594 poultry meat Nutrition 0.000 description 15
- 239000000843 powder Substances 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 12
- 239000012535 impurity Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000012467 final product Substances 0.000 description 8
- 238000000703 high-speed centrifugation Methods 0.000 description 8
- 239000012982 microporous membrane Substances 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- 238000005057 refrigeration Methods 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 210000003932 urinary bladder Anatomy 0.000 description 7
- 230000009278 visceral effect Effects 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000003746 feather Anatomy 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 4
- 235000003805 Musa ABB Group Nutrition 0.000 description 4
- 240000008790 Musa x paradisiaca Species 0.000 description 4
- 241000972672 Phellodendron Species 0.000 description 4
- 235000015266 Plantago major Nutrition 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000000626 ureter Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 241000722953 Akebia Species 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 244000183914 Dianthus superbus Species 0.000 description 3
- 235000013535 Dianthus superbus Nutrition 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 244000292697 Polygonum aviculare Species 0.000 description 3
- 235000006386 Polygonum aviculare Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 208000026500 emaciation Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000000273 veterinary drug Substances 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000132011 Atractylodes lancea Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000561734 Celosia cristata Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 240000001972 Gardenia jasminoides Species 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- -1 atractyl alcohol Chemical compound 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000001520 comb Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- 244000144992 flock Species 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000003771 laboratory diagnosis Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 239000010871 livestock manure Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- YJHVMPKSUPGGPZ-UHFFFAOYSA-N Dihydro-beta-eudesmol Natural products C1CC(C(C)(C)O)CC2C(C)CCCC21C YJHVMPKSUPGGPZ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010048469 Kidney enlargement Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 241000533950 Leucojum Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000737253 Lygodium japonicum Species 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 241001571764 Lysimachia christinae Species 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 1
- 244000171085 Polyporus umbellatus Species 0.000 description 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- XFSVWZZZIUIYHP-UHFFFAOYSA-N beta-Eudesmol Natural products CC(C)(O)C1CCC2CCCC(=C)C2C1 XFSVWZZZIUIYHP-UHFFFAOYSA-N 0.000 description 1
- BOPIMTNSYWYZOC-VNHYZAJKSA-N beta-eudesmol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(C)(O)C)CC[C@]21C BOPIMTNSYWYZOC-VNHYZAJKSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960003191 potassium methylparaben Drugs 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008843 wulingsan Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese veterinary medicines, and in particular relates to a traditional Chinese medicine composition for treating/preventing avian gout and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 35-45 parts of longhairy antenoron herb, 24-31 parts of amur corktree bark, 18-25 parts of swordlike atractylodes rhizome and 10-15 parts of cassia twig. The traditional Chinese medicine composition provided by the invention can promote the immune function of an organism and improve the growth state while curing diseases; the traditional Chinese medicine composition can inhibit the excessive generation of uric acid, promote the excretion of uric acid, regulate the electrolyte balance of the organism, prevent secondary infection and increase the disease resistance of the organism.
Description
Technical Field
The invention relates to the technical field of traditional Chinese veterinary medicines, and particularly relates to a traditional Chinese medicine composition for treating/preventing avian gout and a preparation method and application thereof.
Background
The avian gout is a nutritional metabolic disorder disease caused by excessive uric acid accumulation in blood due to purine metabolic disorder, excessive uric acid production in vivo and excretion disorder, and further causes deposition of urate in vivo. Since birds do not have urea synthase in their bodies and arginase in their livers, nucleic acids or purines cannot synthesize urea from ammonia via the ornithine cycle. Nucleic acids and purine compounds taken into the body are catabolized to produce hypoxanthine and xanthine, and under the action of xanthine oxidase, hypoxanthine is converted into xanthine, and xanthine is oxidized into uric acid. Most of uric acid produced is excreted through the kidney, and the rest is excreted through the intestinal tract. When the metabolism of nucleic acid and purine substances is disturbed due to various reasons, the uric acid concentration in blood is increased, the uric acid is deposited in the body, the uric acid is difficult to dissolve in water, and urate is easy to form, so that the deposition in renal tubules, viscera and joint cavities is caused. The kidney is an important organ for poultry to excrete uric acid, and the kidney damage can cause the damage of the kidney function, further cause the decrease of the clearance rate of uric acid in blood to cause the increase of the concentration of uric acid in blood on one hand, and seriously influence the excretion of uric acid on the other hand, cause the accumulation in the body and cause gout.
The gout of birds is mainly manifested by symptoms of hyperuricemia, gouty arthritis, urate deposition, joint deformity and the like, and is characterized by emaciation, weakness, arthrocele, dyskinesia and diarrhea of sick birds. Clinically, the appetite is obviously reduced or abolished, the spirit is cachexia, and the eyes are blocked and dull; the beard of the head is pale, loose and the water drinking amount is obviously increased, the feathers are lusterless and unhairing, the feathers near the anus are stuck with white feces, and the white loose feces are excreted. The egg yield of the laying hens is reduced, and even the production is stopped. During the autopsy, white urate deposits were observed on the visceral serosal surfaces of the chest, abdominal cavity, heart, etc. The kidney is swollen, the color is light, partial bleeding exists, the surface is in a spot shape, white urate microdots can be seen on the section, the ureter is dilated, and lime-like precipitates are contained in the lumen. They are classified into visceral gout and articular gout according to the etiology and clinical symptoms of the disease, and sometimes they may occur simultaneously. Visceral gout is mainly clinically common and causes serious economic loss for breeding production, the visceral gout is not obvious in seasons, the age of the disease is not obvious, the disease causes are complex, and poultry such as chickens, geese, pigeons and the like can suffer from the visceral gout. In the method, visceral gout is mainly used in chickens, and visceral gout with joint gout is mostly used in geese. The causes of gout of poultry are more than 20, and mainly comprise nutritional metabolic factors, infectious factors, toxic factors, feeding management factors and the like. The avian gout is one of the common avian diseases in China, the morbidity and mortality are high, and the morbidity is 15-50 percent and can reach more than 80 percent at most; the death rate is more than 10 percent, and sometimes the death rate can reach 30 to 50 percent, thereby bringing huge economic loss to the breeding industry. In recent years, the incidence of the disease tends to increase in chickens raised on a large scale.
At present, no good treatment method exists at present because the pathogenesis of the poultry gout is complex. The clinical medicine treatment measures are mainly (1) allopurinol and febuxostat for inhibiting the activity of xanthine oxidase and further inhibiting the generation of uric acid; (2) benzbromarone, probenecid, which promotes uric acid excretion; (3) chemicals such as urotropine which can be combined with urate to form soluble salts and excreted out of the body through the kidney, ammonium chloride which acidifies urine, colchicine which can relieve clinical symptoms, etc. are used. However, the side effects of the medicines are great after long-term use, so that the immunity of the poultry is reduced, the poultry has serious hepatotoxicity and hepatotoxicity, intestinal bleeding and other toxic effects, and meanwhile, the medicine residues are caused, and the product quality and safety of the poultry are reduced. The use of allopurinol and other drugs is extremely costly, and can also cause new adverse consequences since ammonia synthesized in vivo cannot be efficiently converted into uric acid.
The veterinary drug has a large amount of clinical application in the use of gout treatment, and although the traditional Chinese veterinary drug prescription in the prior art has a certain curative effect, the traditional Chinese veterinary drug prescription still has extremely high drug cost; the formula of the formula is complex and is not suitable for large-scale production; the product is mainly prepared from the powder, is not suitable for the symptoms of poultry digestive tract physiological characteristics and obvious reduction of feed intake during morbidity, and has less absorption and poorer treatment effect after use. Some traditional Chinese medicine compositions for preventing and treating the poultry gout have not ideal treatment effect but also undefined effect on waterfowls such as geese and the like.
Therefore, by utilizing the abundant Chinese medicinal material resources in China and researching the traditional Chinese medicine and the theory of Chinese veterinary medicine, the Chinese medicinal composition for treating/preventing the avian gout, which has the advantages of scientific compatibility, simple components, definite curative effect, no side effect, no drug resistance, no drug residue, safety, high efficiency and environmental protection, is urgently provided, and has very important production practice significance.
Disclosure of Invention
In order to solve the defects of the prior art, the invention provides the traditional Chinese medicine composition for treating/preventing the avian gout, which not only can make up the defects of more medicine residues, large toxic and side effects and the like of the existing treatment medicines, but also has the characteristics of low cost, suitability for the physiological structure of poultry, suitability for large-scale production in factories and better treatment effect.
The specific technical scheme provided by the invention is as follows:
the invention aims to provide a traditional Chinese medicine composition for treating/preventing avian gout, which comprises the following raw materials in parts by weight: 35-45 parts of longhairy antenoron herb, 24-31 parts of amur corktree bark, 18-25 parts of swordlike atractylodes rhizome and 10-15 parts of cassia twig.
Preferably, the feed additive comprises the following raw materials in parts by weight: 36-42 parts of longhairy antenoron herb, 25-29 parts of amur corktree bark, 20-24 parts of swordlike atractylodes rhizome and 11-15 parts of cassia twig.
Preferably, the feed additive comprises the following raw materials in parts by weight: 38 parts of longhairy antenoron herb, 27 parts of amur corktree bark, 22 parts of swordlike atractylodes rhizome and 13 parts of cassia twig.
The invention also aims to provide a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
weighing herba Lysimachiae Christinae, cortex Phellodendri, rhizoma Atractylodis and ramulus Cinnamomi according to weight parts, mixing, extracting with water and/or alcohol as extraction solvent, and concentrating the extractive solution.
Preferably, the extraction is ultrasonic extraction for 1 to 3 times at the power of 35kHz to 45kHz and at the temperature of 70 ℃ to 90 ℃, and each time lasts for 0.5h to 1.0 h;
adding water into the medicinal material mixture according to the mass ratio of 1kg to 5-8L for soaking for 1.0-2.0 h before extraction, and crushing the medicinal material mixture to the particle size of 300-450 mu m before soaking in water; adding water to 7-9 times of the total weight of the medicinal materials after soaking;
the concentration is to concentrate the extracting solution to 1.2 to 1.5 times of the total weight of the medicinal materials under the conditions of-0.06 Mpa to-0.15 Mpa and 65 to 80 ℃;
and (3) concentrating the extracting solution, standing for 12-18 h at the temperature of 2-8 ℃, centrifuging at 8000-10000 rpm, adjusting the pH of the obtained centrifugal supernatant to 6.5-7.5, filtering, and collecting filtrate.
The invention also aims to provide application of the traditional Chinese medicine composition in preparing medicines for treating and/or preventing avian gout.
The invention also aims to provide a medicine for treating/preventing the avian gout, which comprises the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials or carriers.
The invention also aims to provide the oral liquid for treating/preventing the avian gout, which is prepared from 50-80 parts by weight of the traditional Chinese medicine composition and 20-50 parts by weight of auxiliary materials.
The invention also aims to provide a compound feed for treating/preventing the gout of the poultry, which is prepared from 50-80 parts by weight of the traditional Chinese medicine composition and 20-50 parts by weight of the feed.
The invention also aims to provide a feed additive for treating/preventing the poultry gout, which is prepared from 50-80 parts by weight of the traditional Chinese medicine composition and 20-50 parts by weight of auxiliary materials.
Compared with the prior art, the invention has the beneficial effects that:
(1) the traditional Chinese medicine composition is prepared on the basis of the theories of traditional Chinese medicine and Chinese veterinarian, and the treatment rules of clearing away damp heat, removing stasis, inducing diuresis for treating stranguria (inducing diuresis for removing dampness and removing calculus for treating stranguria) and strengthening the spleen and nourishing the stomach are selected, the selection and the dosage of the traditional Chinese medicine composition are scientifically and reasonably researched by the pharmacology and pharmacodynamics of the system, the traditional Chinese medicine composition has obvious effect on treating the avian gout, and the traditional Chinese medicine composition is different from the prior art which only treats the clinical symptoms of the avian gout, and can remove the cause of disease by treating the symptoms, so that the disease is thoroughly cured.
(2) The traditional Chinese medicine composition is a pure traditional Chinese medicine extraction preparation, does not contain chemical drugs and antibiotics, is non-toxic, has no drug residue, and is green and environment-friendly.
(3) The raw materials applied by the invention are common medicinal materials in the market, are low in price and easy to obtain, have low cost and are suitable for clinical popularization and use.
(4) The traditional Chinese medicine composition can improve the immunity of the organism and improve the growth state while curing diseases; the traditional Chinese medicine composition can inhibit the excessive generation of uric acid, promote the excretion of uric acid, regulate the electrolyte balance of the organism, prevent secondary infection and increase the disease resistance of the organism.
(5) The preparation method of the traditional Chinese medicine composition adopts the processes of crushing, sieving, soaking and the like of medicinal materials in advance, effectively removes impurities, increases the specific surface area of the medicinal materials, obviously increases the dissolution rate of medicinal substances, adopts an ultrasonic extraction technology for extraction, obviously increases the biological activity of a medicinal extract, has simple and convenient process, saves energy, is efficient, saves time, has short production period and greatly reduces the production cost.
(6) The traditional Chinese medicine composition is used for preparing medicines, feeds or feed additives for treating/preventing the avian gout, and has an excellent effect of treating the avian gout.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
The invention relates to a traditional Chinese medicine composition for treating/preventing avian gout, which is prepared from the following raw materials in parts by weight: 35-45 parts of longhairy antenoron herb, 24-31 parts of amur corktree bark, 18-25 parts of swordlike atractylodes rhizome and 10-15 parts of cassia twig.
Jin Qian Cao, slightly cold in nature, sweet and salty in flavor, enters liver, gallbladder, kidney and bladder meridians. Has the effects of clearing heat, promoting diuresis, treating stranguria, clearing liver and gallbladder damp-heat, and clearing heat and detoxicating, and is mainly used for treating heat stranguria, stranguria with stone, liver and gallbladder calculus, jaundice, toxic heat, carbuncle and swelling, etc. The main components are flavonoids such as kaempferide and quercetin, phenols, tannin, volatile oil, amino acids, choline, sterol, lactones, etc., and have pharmacological effects of promoting bile secretion and excretion, inducing diuresis and removing urinary calculus, promoting bile secretion and excretion, resisting inflammation, resisting bacteria, etc.
Huang Bai is cold in nature and bitter in taste, and enters kidney, bladder and large intestine meridians. Has effects of clearing heat, eliminating dampness, clearing pathogenic fire, removing toxic substance, and eliminating deficiency heat, and can be used for treating dysentery, jaundice, leukorrhagia, heat stranguria, pyocutaneous disease, toxic swelling, eczema, and fever due to yin deficiency. The main components are berberine, phellodendrine, magnoflorine, tetrandrine, jateorhizine, isocupressin, phellodendron lactone, phellodendron ketone and the like, and the pharmaceutical composition has the pharmacological effects of resisting bacteria, reducing blood pressure, relaxing muscles, reducing blood sugar, resisting inflammation, resisting arrhythmia, resisting gastric ulcer, resisting platelet aggregation, resisting anoxia, resisting oxidation and the like.
Cang Zhu is warm in nature, pungent and bitter in flavor and enters spleen and stomach meridians. Has effects of eliminating dampness, invigorating spleen, and dispelling pathogenic wind and dampness, and can be used for treating damp obstruction of middle warmer, diarrhea, wind cold with dampness syndrome, arthralgia due to dampness, and atrophy 36484. The main components are atractylis lancea volatile oil, atractyl alcohol, beta-eudesmol, atractylone, inulin and the like, and the atractylis lancea volatile oil has pharmacological effects of protecting liver, tranquilizing, resisting tumors, resisting bacteria, reducing blood sugar, inducing diuresis and the like.
Gui Zhi, warm in nature, pungent and sweet in flavor, enters heart, lung and bladder meridians. Has effects of inducing sweat, relieving exterior syndrome, warming channels and activating yang, and can be used for treating wind-cold exterior deficiency syndrome, wind-cold exterior excess syndrome, wind-cold-dampness arthralgia syndrome, edema and dysuria. The main ingredients are cassia oil, cinnamaldehyde and the like, and the medicine has the pharmacological effects of relieving fever and sweating, tranquilizing and resisting convulsion, relieving pain, dilating blood vessels, improving blood circulation, resisting pathogens, promoting urination, invigorating stomach, strengthening heart and the like.
Gout, also known as "Baihu joint" in the theory of traditional Chinese medicine, belongs to the category of damp-heat arthralgia syndrome, and is the syndrome of wind-damp-heat arthralgia. The main reasons are wind, dampness, heat and pathogenic factors attacking the body. Disharmony of the zang-fu organs and congenital disorder can lead to qi stagnation and qi deficiency. Disorder of qi movement, abnormal ascending and descending, disturbance of water metabolism, retention of damp pathogen, stagnation of qi and blood, accumulation of heat for a long time, and injection into joints, resulting in obstruction of qi and blood and unsmooth blood vessels. While dampness is heavy, turbid and sticky, which tends to obstruct qi movement. According to the dialectical theory of Chinese veterinarian, the causes of the gout of the birds are liver and gall depression and bladder damp-heat, which are similar to the stranguria caused by sand stone and heat stranguria. Damp-heat obstructing the spleen failing to transport and transform. Invasion of exogenous pathogenic factors can cause combined diseases. Damp-heat is accumulated in the lower energizer to injure the bladder and the bladder fails to function properly, causing dribbling of urine, which may lead to accumulation of damp-heat in the bladder over a long period of time, burning of urine, and coagulation of urine impurities, such as sand and stones, which may accumulate in the urinary bladder and urethra, affecting the discharge of urine.
The invention is based on the theory of traditional Chinese medicine and Chinese veterinarian, and determines to adopt the therapeutic principles of clearing away damp-heat, removing stasis, inducing diuresis for treating stranguria (inducing diuresis for removing dampness and removing urinary calculus for treating stranguria), strengthening spleen and nourishing stomach. The Chinese herba Desmodii Styracifolii is used as a monarch drug in the formula, has the effects of clearing heat and promoting diuresis, treating stranguria, and clearing damp-heat in liver and gallbladder, and is a key drug for treating heat stranguria or urolithic stranguria; phellodendron bark, cortex Phellodendri, radix Et rhizoma Rhei, cortex Phellodendri, radix Angelicae sinensis, radix rehmanniae Preparata, radix rehmanniae Preparata, radix rehmanniae Preparata, and radix rehmanniae Preparata; the rhizoma atractylodis is also a ministerial drug, has aromatic dryness, can eliminate dampness and strengthen spleen, is used for clearing heat and eliminating dampness by matching spleen damp stagnation, damp obstruction of middle energizer, spleen failure in transportation and transportation, damp-heat invasion of lower energizer and bitter and cold phellodendron, and has more obvious effect; cassia twig, ramulus Cinnamomi, as an adjuvant drug, has the effects of warming yang, resolving fluid retention, regulating qi, inducing diuresis, and calming the adverse-rising energy. Benefiting lung qi and opening striae, it is good for qi transformation of triple energizer bladder, promoting the circulation of body fluid and water.
The present invention will be further explained with reference to specific examples and comparative examples.
Example 1
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from herba Lysimachiae Christinae, cortex Phellodendri, rhizoma Atractylodis and ramulus Cinnamomi by weight: 36 parts of longhairy antenoron herb, 30 parts of amur corktree bark, 20 parts of swordlike atractylodes rhizome and 12 parts of cassia twig.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
removing impurities from the 4 medicinal materials, weighing, pulverizing into coarse powder with particle size of 400 μm, mixing, adding 6 times of purified water, and soaking for 1.5 hr; adding purified water into the soaked medicinal materials and soaking solution to 8 times of the weight of the medicinal materials, and performing ultrasonic extraction at frequency of 35kHz and temperature of 80 deg.C for 2 times, each for 45 min; combining the medicinal material extracting solutions obtained for 2 times, concentrating the liquid medicine under the conditions of 75 ℃ and vacuum degree of-0.09 Mpa, filtering the liquid medicine after the liquid medicine is concentrated to be 1.3 times of the amount of the original medicinal material, and standing the medicinal material extracting solution in a cold storage at the temperature of 2-8 ℃ for 15 hours; taking out the medicinal material extract which is kept stand for 15h in a refrigeration house, carrying out online high-speed centrifugation at 9000rpm until the precipitate and the supernatant are in an obvious layered state, and filtering the liquid medicine again after centrifugation; adjusting pH of the centrifugate to 7.2, filtering with 0.22 μm microporous membrane, collecting filtrate, adding adjuvants, packaging, and sterilizing to obtain the final product.
The traditional Chinese medicine composition can be further prepared into a medicine or feed additive for treating/preventing the poultry gout after being added with auxiliary materials, and can also be mixed with common feed to prepare compound feed. The mass ratio of the traditional Chinese medicine composition to the auxiliary materials or the common feed is 50-80: 20-50.
Wherein, the dosage form of the medicine can be oral liquid, granules, superfine powder, tablets or pills. The medicine in different dosage forms is prepared from conventional adjuvants, such as antioxidant, pH regulator, and antiseptic, wherein the antioxidant can be selected from sodium sulfite, sodium pyrosulfite, sodium thiosulfate, EDTA-Na 2 One or more of hydrochloric acid, phosphoric acid and its salts, and fructus Citri Limoniae as pH regulatorAcid and one or more of citrate, lactic acid and NaOH, and the antiseptic can be one or more of benzoic acid, sodium benzoate, parabens, sorbic acid and potassium sorbate.
When the Chinese medicinal composition is mixed with adjuvants to prepare feed additive, the adjuvants can be selected from antiseptic and diluent, and the adjuvants can be selected from at least one of potassium sorbate, methyl paraben or ethyl paraben.
Example 2
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from herba Lysimachiae Christinae, cortex Phellodendri, rhizoma Atractylodis and ramulus Cinnamomi by weight: 38 parts of longhairy antenoron herb, 27 parts of amur corktree bark, 22 parts of swordlike atractylodes rhizome and 13 parts of cassia twig.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
removing impurities from the 4 medicinal materials, weighing, pulverizing into coarse powder with particle size of 400 μm, mixing, adding 6 times of purified water, and soaking for 1.5 hr; adding purified water into the soaked medicinal materials and soaking solution to 8 times of the weight of the medicinal materials, and performing ultrasonic extraction at frequency of 35kHz and temperature of 80 deg.C for 2 times, each for 45 min; combining the medicinal material extracting solutions obtained for 2 times, concentrating the liquid medicine under the conditions of 75 ℃ and vacuum degree of-0.09 Mpa, filtering the liquid medicine after the liquid medicine is concentrated to be 1.3 times of the amount of the original medicinal material, and standing the medicinal material extracting solution in a cold storage at the temperature of 2-8 ℃ for 15 hours; taking out the medicinal material extract which is kept still for 15h in a refrigeration house, carrying out online high-speed centrifugation at 9000rpm, and filtering the liquid medicine again after centrifugation; adjusting pH of the centrifugate to 7.2, filtering with 0.22 μm microporous membrane, collecting filtrate, adding adjuvants, packaging, and sterilizing to obtain the final product.
Example 3
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from herba Lysimachiae Christinae, cortex Phellodendri, rhizoma Atractylodis and ramulus Cinnamomi by weight: 40 parts of longhairy antenoron herb, 25 parts of amur corktree bark, 20 parts of swordlike atractylodes rhizome and 10 parts of cassia twig.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
removing impurities from the 4 medicinal materials, weighing, pulverizing into coarse powder with particle size of 400 μm, mixing, adding 6 times of purified water, and soaking for 1.5 hr; adding purified water into the soaked medicinal materials and soaking solution to 8 times of the weight of the medicinal materials, and performing ultrasonic extraction at frequency of 35kHz and temperature of 80 deg.C for 2 times, each for 45 min; combining the medicinal material extracting solutions obtained for 2 times, concentrating the liquid medicine under the conditions of 75 ℃ and-0.09 Mpa vacuum degree, filtering the liquid medicine after the liquid medicine is concentrated to be 1.3 times of the amount of the original medicinal material, and standing the medicinal material extracting solution in a cold storage at the temperature of 2-8 ℃ for 15 hours; taking out the medicinal material extract which is kept still for 15h in a refrigeration house, carrying out online high-speed centrifugation at 9000rpm, and filtering the liquid medicine again after centrifugation; adjusting pH of the centrifugate to 7.2, filtering with 0.22 μm microporous membrane, collecting filtrate, adding adjuvants, packaging, and sterilizing to obtain the final product.
Example 4
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from herba Lysimachiae Christinae, cortex Phellodendri, rhizoma Atractylodis and ramulus Cinnamomi by weight: 45 parts of longhairy antenoron herb, 24 parts of amur corktree bark, 25 parts of swordlike atractylodes rhizome and 15 parts of cassia twig.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
removing impurities from the 4 medicinal materials, weighing, pulverizing into coarse powder with particle size of 400 μm, mixing, adding 6 times of purified water, and soaking for 1.5 hr; adding purified water into the soaked medicinal materials and soaking solution to 8 times of the weight of the medicinal materials, and performing ultrasonic extraction at frequency of 35kHz and temperature of 80 deg.C for 2 times, each for 45 min; combining the medicinal material extracting solutions obtained for 2 times, concentrating the liquid medicine under the conditions of 75 ℃ and-0.09 Mpa vacuum degree, filtering the liquid medicine after the liquid medicine is concentrated to be 1.3 times of the amount of the original medicinal material, and standing the medicinal material extracting solution in a cold storage at the temperature of 2-8 ℃ for 15 hours; taking out the medicinal material extract which is kept still for 15h in a refrigeration house, carrying out online high-speed centrifugation at 9000rpm, and filtering the liquid medicine again after centrifugation; adjusting pH of the centrifugate to 7.2, filtering with 0.22 μm microporous membrane, collecting filtrate, adding adjuvants, packaging, and sterilizing to obtain the final product.
Example 5
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from herba Lysimachiae Christinae, cortex Phellodendri, rhizoma Atractylodis and ramulus Cinnamomi by weight: 40 parts of longhairy antenoron herb, 25 parts of amur corktree bark, 25 parts of swordlike atractylodes rhizome and 10 parts of cassia twig.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
removing impurities from the 4 medicinal materials, weighing, pulverizing into coarse powder with particle size of 400 μm, mixing, adding 6 times of purified water, and soaking for 1.5 hr; adding purified water into the soaked medicinal materials and soaking solution to 8 times of the weight of the medicinal materials, and performing ultrasonic extraction at frequency of 35kHz and temperature of 80 deg.C for 2 times, each for 45 min; combining the medicinal material extracting solutions obtained for 2 times, concentrating the liquid medicine under the conditions of 75 ℃ and-0.09 Mpa vacuum degree, filtering the liquid medicine after the liquid medicine is concentrated to be 1.3 times of the amount of the original medicinal material, and standing the medicinal material extracting solution in a cold storage at the temperature of 2-8 ℃ for 15 hours; taking out the medicinal material extract which is kept still for 15h in a refrigeration house, carrying out online high-speed centrifugation at 9000rpm, and filtering the liquid medicine again after centrifugation; adjusting pH of the centrifugate to 7.2, filtering with 0.22 μm microporous membrane, collecting filtrate, adding adjuvants, packaging, and sterilizing to obtain the final product.
Example 6
The traditional Chinese medicine composition for treating/preventing the avian gout is different from the preparation method of the embodiment 1, and specifically comprises the following steps:
removing impurities from 4 medicinal materials, weighing, pulverizing into coarse powder with particle diameter of 300 μm, mixing, adding 8 times of purified water, and soaking for 1.0 h; adding purified water into the soaked medicinal materials and soaking solution to 9 times of the medicinal materials, and performing ultrasonic extraction at 70 deg.C and 45kHz for 3 times each for 30 min; combining the medicinal material extracting solutions for 3 times, concentrating the liquid medicine under the conditions of 80 ℃ and-0.06 Mpa vacuum degree, filtering the liquid medicine after the liquid medicine is concentrated to be 1.3 times of the amount of the original medicinal material, and standing the medicinal material extracting solution in a cold storage at the temperature of 2-8 ℃ for 18 hours; taking out the medicinal material extract which is kept stand in a refrigeration house for 18h, carrying out online high-speed centrifugation at 8000rpm, and filtering the liquid medicine again after centrifugation; adjusting pH of the centrifugate to 6.5, filtering with 0.45 μm microporous membrane, collecting filtrate, adding adjuvants, packaging, and sterilizing to obtain the final product.
Example 7
The traditional Chinese medicine composition for treating/preventing the avian gout is different from the preparation method of the embodiment 1, and specifically comprises the following steps:
removing impurities from 4 medicinal materials, weighing, pulverizing into coarse powder with particle size of 450 μm, mixing, adding 5 times of purified water, and soaking for 2.0 hr; adding purified water into the soaked medicinal materials and soaking solution to 7 times of the weight of the medicinal materials, performing ultrasonic extraction, wherein the ultrasonic extraction frequency is 45kHz, the temperature is 90 ℃, extracting for 60min, collecting extracting solution, concentrating the liquid medicine under the conditions of 65 ℃ and-0.15 Mpa vacuum degree, filtering the liquid medicine after the liquid medicine is concentrated to 1.5 times of the amount of the original medicinal materials, and standing the medicinal material extracting solution in a cold storage at the temperature of 2-8 ℃ for 12 h; taking out the medicinal material extract which is kept stand for 12h in a refrigeration house, carrying out online high-speed centrifugation at 10000rpm, and filtering the liquid medicine again after centrifugation; adjusting pH of the centrifugate to 7.5, filtering with 0.45 μm microporous membrane, collecting filtrate, adding adjuvants, packaging, and sterilizing to obtain the final product.
Comparative example 1
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from herba Lysimachiae Christinae, cortex Phellodendri, rhizoma Atractylodis and ramulus Cinnamomi by weight: 33 parts of longhairy antenoron herb, 33 parts of amur corktree bark, 30 parts of swordlike atractylodes rhizome and 20 parts of cassia twig.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
removing impurities from the 4 medicinal materials, weighing, pulverizing into coarse powder with particle size of 400 μm, mixing, adding 6 times of purified water, and soaking for 1.5 hr; adding purified water into the soaked medicinal materials and soaking solution to 8 times of the weight of the medicinal materials, and performing ultrasonic extraction at frequency of 35kHz and temperature of 80 deg.C for 2 times, each for 45 min; combining the medicinal material extracting solutions obtained for 2 times, concentrating the liquid medicine under the conditions of 75 ℃ and-0.09 Mpa vacuum degree, filtering the liquid medicine after the liquid medicine is concentrated to be 1.3 times of the amount of the original medicinal material, and standing the medicinal material extracting solution in a cold storage at the temperature of 2-8 ℃ for 15 hours; taking out the medicinal material extract which is kept still for 15h in a refrigeration house, carrying out online high-speed centrifugation at 9000rpm, and filtering the liquid medicine again after centrifugation; adjusting pH of the centrifugate to 7.2, filtering with 0.22 μm microporous membrane, collecting filtrate, adding adjuvants, packaging, and sterilizing to obtain the final product.
Comparative example 2
Wuling san (pharmacopeia formula): is prepared from poria cocos wolf 100g, alisma orientale 200g, polyporus umbellatus 100g, Cinnamomum cassia 50g, white atractylodes rhizome 100g and five kinds of medicinal materials through disintegrating, sieving and mixing. The dosage is 2g per 1kg feed.
Comparative example 3
Powder of eight ingredients (pharmacopeia formula): is prepared from 30g of caulis aristolochiae manshuriensis, 30g of fringed pink, 30g of polygonum aviculare, 30g of plantain seed, 60g of talcum, 25g of liquorice, 30g of fried gardenia, 30g of processed rhubarb (processed with wine), 15g of rush and nine medicinal materials through crushing, sieving and uniformly mixing. The dosage is 5g per 1kg feed.
Comparative example 4
According to a prescription and a using method aiming at the avian gout in a veterinary prescription manual (3 rd edition) published by China agricultural publishing company in 2013, 50g of rhizoma alismatis, 50g of poria cocos, 30g of plantain seed, 20g of polygonum aviculare, 20g of talc, 20g of spora lygodii, 10g of rheum officinale, 10g of licorice root tip, 10g of fringed pink, 10g of cape jasmine fruit and 10g of achyranthes root are taken. The decoction is taken with 200 dosages of feather chicken, the medicine residue is ground into powder and mixed with feed for feeding, 1 dose every other day, and 3 doses are taken continuously.
Comparative example 5
According to a prescription aiming at the avian gout disease and a using method thereof in Chinese veterinary medicine published by China agricultural press in 2006, 500g of akebia stem, plantain seed, dianthus superbus, polygonum aviculare, gardenia and rhubarb are taken respectively, 200g of talcum and liquorice are taken respectively, and 400g of lysimachia christinae and lygodium japonicum are taken respectively. The application method comprises the following steps: grinding into fine powder, mixing with 150kg feed, and feeding 1000 chickens for 2 days.
Comparative example 6
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from herba Lysimachiae Christinae, rhizoma Atractylodis and ramulus Cinnamomi by weight: 36 parts of desmodium, 20 parts of rhizoma atractylodis and 12 parts of cassia twig.
The preparation method is the same as example 1.
Comparative example 7
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from semen plantaginis, rhizoma atractylodis and cassia twig, and comprises the following components in parts by weight: 36 parts of plantain seed, 20 parts of rhizoma atractylodis and 12 parts of cassia twig.
The preparation method is the same as example 1.
Comparative example 8
A traditional Chinese medicine composition for treating/preventing avian gout is prepared from akebia stem, phellodendron bark, rhizoma atractylodis and cassia twig, and comprises the following components in parts by weight: 36 parts of akebia stem, 30 parts of phellodendron, 20 parts of rhizoma atractylodis and 12 parts of cassia twig.
Experiment 1:
laboratory test for avian gout
1700 sea blue brown laying hens of 60 days old are immunized according to a conventional immunization program of the laying hens, and are fed with high-protein and high-calcium feed (the protein content is more than or equal to 28 percent, and the calcium content is more than or equal to 6 percent) to prepare a chicken gout model, and drinking water is limited every day, and the chicken gout model is continuously fed for 10 days. After the tested chicken has listlessness, anorexia, sharp increase of drinking desire, thin and white feces, and the typical gout diseases such as the surface of visceral organs has urate deposits, the kidney has swollen and white blood, the surface and the essence have snowflake patterns, ureter swelling, and the content of blood uric acid exceeds 480 mu mol/L, the chicken is fed by replacing normal feed, and the medication is started.
Randomly dividing test chickens into a model group, an allopurinol group, examples 1-7 groups and comparative examples 1-8 groups, wherein each group comprises 100 test chickens; taking 100 healthy chickens of the same age as the day as a normal group, and feeding the normal group with normal feed in the whole process. Specific groups and administration are shown in table 1.
TABLE 1 Experimental groups and dosing
The test results are shown in table 2.
TABLE 2 avian gout laboratory clinical test results
Note: the letter difference indicates that the difference is very significant (P < 0.01); "-" no urate deposition; "+" urate deposition is evident; "+ +" urate was deposited in large amounts. "+ + +" urate deposition was severe.
From the test results, it can be seen that the weight gain effect of the poultry is the best and higher than that of the allopurinol group in example 2 compared with other examples and comparative examples; example 2 can significantly reduce poultry kidney swelling caused by feeding molding feed, and reduce kidney index; example 2 can significantly reduce the blood uric acid content in blood, significantly reduce the deposition of urate, significantly reduce the mortality rate, and has no significant difference from the normal group. Compared with other examples, the formula of the example 2 has the best treatment effect, and can greatly reduce clinical symptoms. Compared with other comparative examples, the proportion range of the embodiment has better effect, can effectively treat the avian gout, saves a large amount of treatment cost, and has better effect.
Experiment 2
20000 laying hens in 3 months in 2021 and in a large-scale chicken farm in Wen water county, Lvliang, Shanxi province are raised to 120 days old, and the laying hens suffer from mental retardation, anorexia, cockscomb pallor, feather disharmony, severe emaciation, discharge of a large amount of white lime-like thin manure and death. The kidney enlargement, ureter dilation and blood uric acid content of more than or equal to 480 mu mol/L can be seen in clinical examination, and the chicken gout is confirmed according to clinical symptoms, examination conditions and laboratory diagnosis. 1500 chickens were selected and the sick chicken flocks were randomly divided into 3 groups of 500 chickens per group. Group 1 was a treatment group, which was administered with drinking water (0.15% (v/v) dose) using the oral liquid prepared in example 2 of the present invention; group 2 was a control group treated with allopurinol (60 mg/kg allopurinol in the feed), group 3 was a blank group without any drug, and the treatment effect was compared after 7 days.
Table 3 results of clinical trials of each group
| Group of | Degree of urate deposition | Blood uric acid content (μmol/L) | Death and culling rate |
| Example 2 | - | 341.73±29.53 B | 5.8％ |
| Allopurinol group | ++ | 398.56±31.25 A | 11.2％ |
| Blank control group | +++ | 587.95±45.82 A | 26.8％ |
Note: the letter difference indicates that the difference is very significant (P < 0.01); "-" no urate deposition; "+" urate deposition is evident; "+ +" urate was deposited in large amounts. "+ + +" urate deposition was severe.
As shown in the test results in table 3, the group in example 2 can significantly reduce the content of uric acid in the sick fowl, significantly reduce the deposition degree of urate in the kidney, and greatly reduce the mortality, which shows that the group in example 2 has a good therapeutic effect, and the effect is superior to that of the allopurinol group.
Experiment 3
8000 laying hens in a certain chicken farm in Jishan county of the province of Shanxi province of transport city in 2021 year old are fed to 90 days old, so that the problems of mental deterioration, anorexia, pale cockscomb, feather disorder, severe emaciation, discharge of a large amount of white lime-like thin manure and death occur. The kidney is enlarged and the ureter is dilated in clinical examination, the content of blood uric acid is more than or equal to 480 mu mol/L, and the chicken gout is diagnosed according to clinical symptoms, examination conditions and laboratory diagnosis. 1200 chickens were selected and the sick chicken flock was randomly divided into 4 groups of 300 chickens per group. Group 1 is a treatment group, and the oral liquid prepared in example 2 of the present invention was administered with drinking water; group 2 was a control group treated with comparative example 2 (at a dose of 2g/kg to feed); group 3 was a control group treated with comparative example 3 (at a dose of 5g/kg to feed) and group 4 was a blank group without any drug and the treatment effect was compared after 7 days.
Table 4 results of clinical trials of each group
| Group of | Degree of urate deposition | Blood uric acid content (μmol/L) | Death and culling rate |
| Example 2 | - | 318.53±18.66 C | 6.3％ |
| Comparative example 2 | ++ | 442.25±27.18 B | 20.7％ |
| Comparative example 3 | ++ | 427.34±32.59 B | 23.0％ |
| Blank control group | +++ | 605.41±45.82 A | 26.8％ |
Note: the letter difference indicates that the difference is very significant (P < 0.01); "-" no urate deposition; "+" urate deposition is evident; "+ +" urate was deposited in large amounts. "+ + +" urate deposition was severe.
As shown in the test results in table 4, the group in example 2 can significantly reduce the content of uric acid in the blood of the sick fowl, significantly reduce the deposition degree of urate in the kidney, and significantly reduce the death and culling rate, which shows that the group in example 2 has a good therapeutic effect, and the therapeutic effect is significantly better than the groups in comparative examples 2 and 3.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. A traditional Chinese medicine composition for treating/preventing avian gout is characterized by comprising the following raw materials in parts by weight: 35-45 parts of longhairy antenoron herb, 24-31 parts of amur corktree bark, 18-25 parts of swordlike atractylodes rhizome and 10-15 parts of cassia twig.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 36-42 parts of longhairy antenoron herb, 25-29 parts of amur corktree bark, 20-24 parts of swordlike atractylodes rhizome and 11-15 parts of cassia twig.
3. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 38 parts of longhairy antenoron herb, 27 parts of amur corktree bark, 22 parts of swordlike atractylodes rhizome and 13 parts of cassia twig.
4. A method for preparing the traditional Chinese medicine composition of any one of claims 1 to 3, which is characterized by comprising the following steps: weighing herba Lysimachiae Christinae, cortex Phellodendri, rhizoma Atractylodis and ramulus Cinnamomi according to weight parts, mixing, extracting with water and/or alcohol as extraction solvent, and concentrating the extractive solution.
5. The method for preparing a Chinese medicinal composition according to claim 4,
the extraction is ultrasonic extraction for 1 to 3 times at the power of 35kHz to 45kHz and the temperature of 70 ℃ to 90 ℃, and each time lasts for 0.5h to 1.0 h;
adding water into the medicinal material mixture according to the mass ratio of 1kg to 5-8L for soaking for 1.0-2.0 h before extraction, and crushing the medicinal material mixture to the particle size of 300-450 mu m before soaking in water; adding water to 7-9 times of the total weight of the medicinal materials after soaking;
the concentration is to concentrate the extracting solution to 1.2 to 1.5 times of the total weight of the medicinal materials under the conditions of-0.06 Mpa to-0.15 Mpa and 65 to 80 ℃;
and (3) concentrating the extracting solution, standing for 12-18 h at the temperature of 2-8 ℃, centrifuging at 8000-10000 rpm, adjusting the pH of the obtained centrifugal supernatant to 6.5-7.5, filtering, and collecting filtrate.
6. Use of the traditional Chinese medicine composition according to any one of claims 1 to 3 in preparation of medicines for treating and/or preventing avian gout.
7. A medicament for treating/preventing avian gout, which comprises the traditional Chinese medicine composition of any one of claims 1 to 3, and a pharmaceutically acceptable adjuvant or carrier.
8. An oral liquid for treating/preventing avian gout, which is characterized by being prepared from 50-80 parts by weight of the traditional Chinese medicine composition as claimed in any one of claims 1-3 and 20-50 parts by weight of auxiliary materials.
9. A compound feed for treating/preventing avian gout, which is characterized by being prepared from 50-80 parts by weight of the traditional Chinese medicine composition according to any one of claims 1-3 and 20-50 parts by weight of the feed.
10. A feed additive for treating/preventing avian gout, which is characterized by being prepared from 50-80 parts by weight of the traditional Chinese medicine composition according to any one of claims 1-3 and 20-50 parts by weight of auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210634557.5A CN114886961A (en) | 2022-06-07 | 2022-06-07 | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210634557.5A CN114886961A (en) | 2022-06-07 | 2022-06-07 | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114886961A true CN114886961A (en) | 2022-08-12 |
Family
ID=82728740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210634557.5A Pending CN114886961A (en) | 2022-06-07 | 2022-06-07 | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114886961A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115844955A (en) * | 2022-12-31 | 2023-03-28 | 西南交通大学 | Chinese veterinary drug 'Tekang' compound preparation and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104224863A (en) * | 2014-06-25 | 2014-12-24 | 苏州凯祥生物科技有限公司 | Application of herba lysimachiae total flavonoids in preparation of medicine for relieving hyperuricemia |
| CN107213239A (en) * | 2017-05-25 | 2017-09-29 | 中国科学院长春应用化学研究所 | A kind of Chinese medicine composition and its preparation method and application |
-
2022
- 2022-06-07 CN CN202210634557.5A patent/CN114886961A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104224863A (en) * | 2014-06-25 | 2014-12-24 | 苏州凯祥生物科技有限公司 | Application of herba lysimachiae total flavonoids in preparation of medicine for relieving hyperuricemia |
| CN107213239A (en) * | 2017-05-25 | 2017-09-29 | 中国科学院长春应用化学研究所 | A kind of Chinese medicine composition and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| 孙兆姝,等: "二妙丸对痛风症大鼠血清炎症介质的影响研究", 辽宁中医杂志 * |
| 王海东,等: "金钱草提取物对高尿酸血症小鼠的影响", 中国中药杂志 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115844955A (en) * | 2022-12-31 | 2023-03-28 | 西南交通大学 | Chinese veterinary drug 'Tekang' compound preparation and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103689296B (en) | Feed for ewe at later pregnancy and lactation period and preparation method thereof | |
| CN110090279B (en) | Traditional Chinese medicine composition for preventing and treating avian gout and preparation and use methods thereof | |
| CN105166544A (en) | Pig mixed feed and preparation method thereof | |
| CN105663546B (en) | Traditional Chinese medicine composition for treating proventriculitis of chicken | |
| CN104543576B (en) | Prevent and treat composite vegetables extractive feed addictive and its preparation method application of grice diarrhoea | |
| CN114886961A (en) | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof | |
| CN105535094A (en) | Traditional Chinese medicine composition for facilitating beast, bird and fish production performance | |
| CN105106394A (en) | Chinese herb preparation for preventing and treating animal digestive canal infection and preparing method and application thereof | |
| CN104547186A (en) | Compound fermented type traditional Chinese medicine for preventing and treating fowl cholera and preparation method of compound fermented type traditional Chinese medicine | |
| CN103393891B (en) | Antiviral compound traditional Chinese medicine for animals, and preparation method and use thereof | |
| CN114366770A (en) | Preparation method of Qiqing Baidu granules | |
| CN103263538B (en) | Traditional Chinese medicine combination with nourishing, anti-inflammation, antidiarrheal, hemostatic and analgesic effects for livestock and preparation method thereof | |
| CN106259159A (en) | A kind of duck culturing method preventing and treating E. coli isolated from ducks | |
| CN107519322B (en) | Traditional Chinese medicine spray for preventing and treating salpingitis of hens in cloacal administration mode | |
| CN115068546B (en) | Traditional Chinese veterinary medicine oral liquid for preventing and treating poultry liver diseases and application thereof | |
| CN116942745B (en) | Traditional Chinese medicine composition for treating salpingitis of laying hens and preparation method thereof | |
| CN114099573B (en) | Traditional Chinese medicine composition for improving egg laying performance of laying hens as well as preparation method and application of traditional Chinese medicine composition | |
| CN111281922B (en) | Compound traditional Chinese veterinary medicine oral preparation for treating diarrhea of pigs and poultry and preparation method thereof | |
| CN116370574B (en) | Traditional Chinese medicine composition for preventing and treating gosling gout and preparation method thereof | |
| CN113181317B (en) | Traditional Chinese medicine composition, preparation method thereof and application thereof in preventing diarrhea or resisting diarrhea | |
| CN114073728B (en) | Traditional Chinese medicine composition for preventing and treating salpingitis of laying hens and preparation method thereof | |
| CN114191510B (en) | Chinese herbal compound preparation for preventing and treating diarrhea of piglets and preparation method thereof | |
| CN113730481B (en) | Traditional Chinese medicine composition for preventing and treating canine parvovirus enteritis, suppository and preparation method | |
| CN111375028B (en) | Preparation and use method of compound traditional Chinese medicine oral liquid for preventing and treating gosling gout | |
| CN106310226A (en) | Chinese herbal medicine compound preparation for preventing and treating piglet dysentery and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220812 |